Asterias Biotherapeutics Company Profile (NYSEMKT:AST)

About Asterias Biotherapeutics

Asterias Biotherapeutics logoAsterias Biotherapeutics, Inc. is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer, and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia. The Company's product development is focused primarily on AST-OPC1 and AST-VAC2. The Company's lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 product consists of glial progenitor cells, which are cells that become glial cells after injection. AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with ribonucleic acid (RNA) for the protein component of human telomerase (hTERT) and a portion of a lysosomal targeting signal (LAMP).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSEMKT
  • Symbol: AST
  • CUSIP:
Key Metrics:
  • Previous Close: $2.73
  • 50 Day Moving Average: $2.91
  • 200 Day Moving Average: $3.62
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.79
  • P/E Growth: 0.00
  • Market Cap: $123.99M
  • Outstanding Shares: 45,418,000
  • Beta: 1.58
Additional Links:
Companies Related to Asterias Biotherapeutics:

Analyst Ratings

Consensus Ratings for Asterias Biotherapeutics (NYSEMKT:AST) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.50

Analysts' Ratings History for Asterias Biotherapeutics (NYSEMKT:AST)
Show:
DateFirmActionRatingPrice TargetDetails
5/26/2016FBR & CoReiterated RatingBuyView Rating Details
5/23/2016Chardan CapitalInitiated CoverageBuy$5.50View Rating Details
5/17/2016Rodman & RenshawReiterated RatingBuy$10.00View Rating Details
8/11/2015MLV & Co.Reiterated RatingBuy$9.00View Rating Details
5/5/2015Lake Street CapitalInitiated CoverageBuy$22.00View Rating Details
(Data available from 8/26/2014 forward)

Earnings

Earnings History for Asterias Biotherapeutics (NYSEMKT:AST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/15/2016Q216($0.19)($0.12)$1.14 million$1.53 millionViewListenView Earnings Details
5/16/2016Q116($0.14)($0.27)$1.60 millionViewListenView Earnings Details
3/29/2016Q415($0.13)($0.13)$1.07 millionViewListenView Earnings Details
11/9/2015Q315($0.11)($0.06)$1.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.10)ViewListenView Earnings Details
5/7/2015($0.13)($0.14)ViewN/AView Earnings Details
3/10/2015($0.13)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Asterias Biotherapeutics (NYSEMKT:AST)
Current Year EPS Consensus Estimate: $-0.77 EPS
Next Year EPS Consensus Estimate: $-0.72 EPS

Dividends

Dividend History for Asterias Biotherapeutics (NYSEMKT:AST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Asterias Biotherapeutics (NYSEMKT:AST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/30/2016Stephen Lahue CarttCEOBuy10,000$2.40$24,000.00View SEC Filing  
6/29/2016Richard T LebuhnDirectorBuy5,000$2.38$11,900.00View SEC Filing  
6/10/2016Stephen Lahue CarttCEOBuy50,000$2.93$146,500.00View SEC Filing  
6/9/2016Alfred D KingsleyDirectorBuy4,000$2.93$11,720.00View SEC Filing  
5/13/2016Natale S RicciardiDirectorBuy14,706$3.39$49,853.34View SEC Filing  
9/15/2015Edward WirthinsiderSell2,880$6.00$17,280.00View SEC Filing  
9/15/2015Katharine E. SpinkCOOSell3,760$6.00$22,560.00View SEC Filing  
6/25/2015Andrew ArnoDirectorBuy5,000$4.32$21,600.00View SEC Filing  
2/9/2015Pedro LichtingerCEOBuy128,205$3.90$499,999.50View SEC Filing  
10/1/2014Scarsdale Equities LlcMajor ShareholderBuy60,000$5.93$355,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Asterias Biotherapeutics (NYSEMKT:AST)
DateHeadline
publicnow.com logoСurrent report No 18/2016 (NYSEMKT:AST)
www.publicnow.com - August 25 at 3:40 PM
News IconLooking Closer at Stocks of Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 25 at 8:26 AM
capitalcube.com logoETF’s with exposure to Asterias Biotherapeutics, Inc. : August 24, 2016 (NYSEMKT:AST)
www.capitalcube.com - August 24 at 11:51 AM
News IconMagnifying Stocks of Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 23 at 8:52 PM
finance.yahoo.com logoASTERIAS BIOTHERAPEUTICS, INC. Financials (NYSEMKT:AST)
finance.yahoo.com - August 23 at 3:38 PM
News IconLet's Take a Closer Look at Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 22 at 8:43 PM
News IconSmall Cap Insight on Shares of Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 20 at 3:38 PM
News IconTaking A Closer Look at Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 18 at 3:45 PM
News IconStock on the Move, Taking A Closer Look at Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 18 at 3:45 PM
capitalcube.com logoAsterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 (NYSEMKT:AST)
www.capitalcube.com - August 18 at 12:00 PM
News IconA Closer Look at Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 17 at 3:39 PM
prnewswire.com logoAsterias Biotherapeutics Reports Second Quarter Results and Highlights Progress of SCiSTAR Study Evaluating AST ... - PR Newswire (press release) (NYSEMKT:AST)
www.prnewswire.com - August 17 at 3:39 PM
4-traders.com logoASTERIAS BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NYSEMKT:AST)
www.4-traders.com - August 17 at 11:48 AM
biz.yahoo.com logoASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement (NYSEMKT:AST)
biz.yahoo.com - August 17 at 11:48 AM
seekingalpha.com logoAsterias Biotherapeutics' (AST) CEO Stephen Cartt on Q2 2016 Results - Earnings Call Transcript (NYSEMKT:AST)
seekingalpha.com - August 16 at 8:53 PM
finance.yahoo.com logoAsterias Biotherapeutics Reports Second Quarter Results and Highlights Progress of SCiSTAR Study Evaluating AST ... - Yahoo Finance (NYSEMKT:AST)
finance.yahoo.com - August 16 at 3:38 PM
reuters.com logoBRIEF-Asterias Biotherapeutics reports loss per share of $0.12 (NYSEMKT:AST)
www.reuters.com - August 15 at 9:09 PM
finance.yahoo.com logoAsterias Biotherapeutics Reports Second Quarter Results and Highlights Progress of SCiSTAR Study Evaluating AST-OPC1 in Spinal Cord Injury Patients (NYSEMKT:AST)
finance.yahoo.com - August 15 at 9:09 PM
sg.finance.yahoo.com logoAsterias Biotherapeutics posts 2Q loss (NYSEMKT:AST)
sg.finance.yahoo.com - August 15 at 9:09 PM
4-traders.com logoBioTime : Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine (NYSEMKT:AST)
www.4-traders.com - August 15 at 10:51 AM
publicnow.com logoASTARTA published interim report for the siх months of 2016 (NYSEMKT:AST)
www.publicnow.com - August 12 at 12:14 PM
finance.yahoo.com logoShould You Buy Asterias Biotherapeutics (AST) Ahead of Earnings? (NYSEMKT:AST)
finance.yahoo.com - August 12 at 12:14 PM
finance.yahoo.com logo3 Healthcare Stocks Poised to Beat Q2 Earnings (NYSEMKT:AST)
finance.yahoo.com - August 11 at 12:51 PM
capitalcube.com logoAstaldi SpA :AST-IT: Earnings Analysis: Q1, 2016 By the Numbers : August 10, 2016 (NYSEMKT:AST)
www.capitalcube.com - August 10 at 9:26 AM
twst.com logoBioTime Inc.: BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments (NYSEMKT:AST)
www.twst.com - August 9 at 10:12 PM
biz.yahoo.com logoASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NYSEMKT:AST)
biz.yahoo.com - August 9 at 4:42 PM
finance.yahoo.com logoBioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments (NYSEMKT:AST)
finance.yahoo.com - August 9 at 4:42 PM
publicnow.com logoASTARTA increased spring crops yields (NYSEMKT:AST)
www.publicnow.com - August 9 at 12:26 PM
kcregister.com logoBig Movers: Asterias Biotherapeutics, Inc. (NYSE:AST), Barrick Gold Corporation (NYSE:ABX), Walt Disney Company ... - KC Register (NYSEMKT:AST)
www.kcregister.com - August 8 at 3:39 PM
prnewswire.com logoAsterias Biotherapeutics to Report Second Quarter Results on August 15, 2016 - PR Newswire (press release) (NYSEMKT:AST)
www.prnewswire.com - August 1 at 8:32 AM
finance.yahoo.com logoAsterias Biotherapeutics to Report Second Quarter Results on August 15, 2016 (NYSEMKT:AST)
finance.yahoo.com - August 1 at 7:30 AM
publicnow.com logoCurrent report No 16/2016 (NYSEMKT:AST)
www.publicnow.com - July 29 at 8:28 AM
News IconHow Many Asterias Biotherapeutics Inc (NYSEMKT:AST)'s Analysts Are Bullish? - Consumer Eagle (NYSEMKT:AST)
www.consumereagle.com - July 22 at 3:35 PM
News IconAsterias Biotherapeutics Inc's Stock Is Buy After Today's Huge Increase - Consumer Eagle (NYSEMKT:AST)
www.consumereagle.com - July 22 at 3:35 PM
capitalcube.com logoAusNet Services Ltd. :AST-AU: Earnings Analysis: For the six months ended March 31, 2016 : July 22, 2016 (NYSEMKT:AST)
www.capitalcube.com - July 22 at 3:01 AM
capitalcube.com logoAusNet Services Ltd. :AST-AU: Earnings Analysis: 2016 By the Numbers : July 22, 2016 (NYSEMKT:AST)
www.capitalcube.com - July 22 at 1:16 AM
News IconStock Moving Lower for the Month; Investor Update on Asterias Biotherapeutics, Inc. (:AST) - Engelwood Daily (NYSEMKT:AST)
www.engelwooddaily.com - July 21 at 3:36 PM
prnewswire.com logoAsterias Biotherapeutics Appoints Ryan Chavez as EVP of Finance and General Counsel - PR Newswire (press release) (NYSEMKT:AST)
www.prnewswire.com - July 20 at 11:42 AM
4-traders.com logoAsterias Biotherapeutics : Appoints Ryan Chavez as EVP of Finance and General Counsel (NYSEMKT:AST)
www.4-traders.com - July 19 at 9:00 PM
News IconAsterias Biotherapeutics Incorporated (NYSEMKT:AST) Short Interest Increased By 29.08% - Press Telegraph (NYSEMKT:AST)
presstelegraph.com - July 19 at 3:36 PM
News IconInvestor Watch: Volatility Recap on Shares of: Asterias Biotherapeutics, Inc. (:AST) - Engelwood Daily (NYSEMKT:AST)
www.engelwooddaily.com - July 19 at 9:48 AM
reuters.com logoBRIEF-Asterias Biotherapeutics appoints Ryan Chavez as general counsel - Reuters (NYSEMKT:AST)
www.reuters.com - July 18 at 8:31 AM
finance.yahoo.com logoAsterias Biotherapeutics Appoints Ryan Chavez as EVP of Finance and General Counsel (NYSEMKT:AST)
finance.yahoo.com - July 18 at 6:30 AM
fiscalstandard.com logoNext Weeks Broker Price Targets For Asterias Biotherapeutics, Inc. (AST) - Fiscal Standard (NYSEMKT:AST)
www.fiscalstandard.com - July 17 at 8:20 AM
News IconIncreased Volatility Noted on Shares of: Asterias Biotherapeutics, Inc. (:AST) - Engelwood Daily (NYSEMKT:AST)
www.engelwooddaily.com - July 16 at 3:35 PM
News IconAsterias Biotherapeutics Incorporated (NYSEMKT:AST) Shorted Shares Increased By 0.48% - Consumer Eagle (NYSEMKT:AST)
www.consumereagle.com - July 16 at 3:35 PM
publicnow.com logoCurrent report No 15/2016 (NYSEMKT:AST)
www.publicnow.com - July 15 at 11:28 AM
News IconAre Analysts Bullish Asterias Biotherapeutics Inc (NYSEMKT:AST) After Last Week? - Press Telegraph (NYSEMKT:AST)
presstelegraph.com - July 14 at 3:40 PM
News IconInvestor Update - Shares Lower in Session: Asterias Biotherapeutics, Inc. (:AST) - Telanagana Press (NYSEMKT:AST)
telanaganapress.com - July 13 at 3:37 PM
News IconWhat's Propelling Asterias Biotherapeutics Inc to Decline So Much? - Consumer Eagle (NYSEMKT:AST)
www.consumereagle.com - July 13 at 3:37 PM

Social


Last Updated on 8/26/2016 by MarketBeat.com Staff